[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"regenerative-medicine\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:regenerative-medicine":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100649557","safe-ips---frances-first-hospital-based-platform-for-the-production-of-induced-pluripotent-stem-cells-for-the-regenerative-medicine-of-the-future-100649557",false,"NCT07735559","SAFE-iPS - France's First Hospital-based Platform for the Production of Induced Pluripotent Stem Cells for the Regenerative Medicine of the Future","SAFE-iPS","Inclusion Criteria:\n\n* Age ≥ 18 years and ≤ 35 years\n* No medical contraindication to a 54 mL blood sample collection\n* Negative viral serology for:\n\n  * Human Immunodeficiency Virus (HIV)\n  * Hepatitis B Virus (HBV)\n  * Hepatitis C Virus (HCV)\n  * Human T-lymphotropic Virus type 1 (HTLV-1)\n* A participant who agrees to have their anonymized biological samples and cell lines stored in a biological sample collection for other research purposes (including genetic research)\n\nExclusion Criteria:\n\n* Any active medical condition\n* Any ongoingl treatment\n* Subjects who cannot read and\u002For write\n* Inability to ensure participant during the study period\n* Participation in another clinical trial or administration of an off-label medication that could interfere with blood test results.\n* Participation in another research protocol involving biological sampling that limits the number of mL to be collected.\n* Failure to obtain informed consent\n* Not enrolled in a social security program,\n* Subject participating in another research study with an ongoing exclusion period\n* Protected populations under the French Public Health Code (women who are giving birth, breastfeeding, or pregnant; subjects deprived of liberty by judicial or administrative decision; adults under legal protection (under any form of guardianship))",true,"ALL","18 Years","35 Years",{"count":21,"type":22},6,"ESTIMATED","INTERVENTIONAL",[25],"NA","The objective of the study is to establish the first French hospital-based Good Manufacturing Practice (GMP)-compliant platform for the production of clinical-grade induced pluripotent stem cells (iPSCs) for future regenerative medicine applications.\n\nThe primary objective is to generate, via the SAFE-iPS platform, 4 clinical-grade iPSC lines derived from peripheral blood samples taken from:\n\n* Two healthy male volunteers\n* Two healthy female volunteers\n\nThese 4 iPSC lines will undergo comprehensive quality assessment including:\n\n* Expression of pluripotency markers\n* Genomic stability assessment\n* Absence of residual Sendai viral integration\n* Technical reproducibility assessment\n* Manufacturing efficiency assessment\n* Preliminary medico-economic evaluation This project aims to demonstrate that the SAFE-iPS manufacturing process can be successfully transferred to a hospital Good Manufacturing Practice (GMP) environment and can reproducibly generate clinical-grade iPSC lines meeting international quality standards for future regenerative medicine applications. It also aims to establish the first French public hospital platform dedicated to routine GMP production of clinical-grade iPSCs.",[28,29],"Regenerative Medicine","Induced Pluripotent Stem Cells (iPSC) Production",[31,32,33,34,35],"Induced pluripotent stem cells (iPSCs),","regenerative medicine,","cell therapy","directed differentiation","clinical-grade production (or GMP manufacturing)","NOT_YET_RECRUITING","2026-07-27",{"date":39,"type":40},"2026-07-30","ACTUAL",{"date":42,"type":22},"2026-11",{"date":44,"type":22},"2028-02",{"name":46,"class":47},"University Hospital, Montpellier","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":48},"100641301","restoregi-study-regenerative-endoscopic-stromal-therapy-outcomes-and-risk-factor-evaluation-in-gi-fistulas-100641301","NCT07661043","RESTOREGI Study: Regenerative Endoscopic Stromal Therapy: Outcomes and Risk Factor Evaluation in GI Fistulas","PROSPECTIVE RISK FACTOR ANALYSIS OF CLINICAL OUTCOMES FOLLOWING ENDOSCOPIC tSVF-em THERAPY FOR BENIGN GASTROINTESTINAL FISTULAS - RESTOREGI Study","RESTORE-GI","Inclusion Criteria:\n\n* Age ≥18 years\n* Confirmed benign gastrointestinal fistula involving the luminal gastrointestinal tract\n* Fistula accessible for endoscopic evaluation and treatment\n* Planned treatment with endoscopic tSVF-EM therapy, with or without adjunctive endoscopic therapies (argon plasma coagulation \\[APC\\], tract abrasion\u002Fcurettage, clips, over-the-scope clips \\[OTSC\\], endoscopic suturing, or stent placement)\n* Ability and willingness to provide written informed consent\n* Willingness to comply with scheduled follow-up visits and study assessments\n\nExclusion Criteria:\n\n* Perianal fistulas of any aetiology\n* Inflammatory bowel disease-associated fistulas, including fistulas related to Crohn's disease or ulcerative colitis\n* Malignancy-related fistulas\n* Fistulas requiring primary oncologic surgical management\n* Uncontrolled sepsis or undrained abscess at baseline (patients may become eligible following adequate drainage and clinical stabilisation)\n* Contraindication to adipose tissue harvest, sedation, anaesthesia, or therapeutic endoscopy\n* Pregnancy or lactation\n* Severe coagulopathy not correctable prior to intervention\n* Inability to provide informed consent\n* Anticipated inability to complete study follow-up\n* Participation in another interventional study that may influence fistula healing outcomes",{"count":58,"type":22},50,[25],"RESTOREGI Study Benign gastrointestinal fistulas are abnormal communications between the gastrointestinal tract and adjacent organs or the skin. Chronic fistulas are often difficult to treat because of persistent inflammation, fibrosis, impaired vascularity, and defective tissue regeneration. Endoscopic regenerative therapy using mechanically processed autologous total stromal vascular fraction-enriched microfragmented adipose tissue (tSVF-EM) has emerged as a novel therapeutic approach that may promote tissue repair through angiogenesis, immunomodulation, and regenerative signaling.\n\nAlthough early clinical experience suggests promising healing outcomes, factors predicting successful fistula closure remain poorly understood. The RESTOREGI study is a prospective, single-center observational cohort study designed to identify patient-related, fistula-related, and procedural factors associated with successful healing following endoscopic tSVF-EM therapy in benign gastrointestinal fistulas. The study will also evaluate treatment safety, time to healing, recurrence rates, and the impact of procedural variables on outcomes.",[62,28,63],"Fistula","Stromal Vascular Fraction",[65,66,67,68,69],"Gastrointestinal fistula","Stromal vascular fraction","Endoscopic fistula closure","Regenerative endoscopy","Mesenchymal stromal cells","2026-06-22",{"date":72,"type":40},"2026-06-24",{"date":74,"type":22},"2026-06-15",{"date":76,"type":22},"2027-08-31",{"name":78,"class":47},"Asian Institute of Gastroenterology, India"]